Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab for Ocular Sequelae in Lyell Syndrome
2025-522556-10-01Phase 2Authorised
- Sponsor
- Toxilyon
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of risankizumab in toxic epidermal necrolysis (TEN) and Toxic epidermal necrolysis (TEN), sponsored by Toxilyon. Primary endpoints: Change in tear film break-up time (TBUT) and Patient-reported ocular symptoms and vision-related quality of life. Planned start Jan 2026; status: authorised.
02
Drugs
risankizumab
03
Conditions
toxic epidermal necrolysis (TEN)Toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on 2025-522556-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522556-10-01.